Moomoo AIのまとめ
Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.
Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.
Allarity Therapeutics, Inc.は、NASDAQ株式市場の銘柄ALLRで上場し、デラウェアに拠点を置く企業として、SECに提出書類を通じて役員の重要な変更を報告しました。新しいマネジメントサービス契約（MSA）により、コンサルティング契約が置き換えられることを明らかにし、2024年6月1日から有効になります。この新しい契約では、Allarity TherapeuticsのCEOであるThomas H. Jensen氏が、毎月$43,750の固定報酬と$100,000の一時的な契約金で彼のサービスを継続することが求められます。MSAには、業績に基づく報酬調整、年次の任意業績...すべて展開
Allarity Therapeutics, Inc.は、NASDAQ株式市場の銘柄ALLRで上場し、デラウェアに拠点を置く企業として、SECに提出書類を通じて役員の重要な変更を報告しました。新しいマネジメントサービス契約（MSA）により、コンサルティング契約が置き換えられることを明らかにし、2024年6月1日から有効になります。この新しい契約では、Allarity TherapeuticsのCEOであるThomas H. Jensen氏が、毎月$43,750の固定報酬と$100,000の一時的な契約金で彼のサービスを継続することが求められます。MSAには、業績に基づく報酬調整、年次の任意業績ボーナスの資格、そして費用の償還が記載されています。また、企業とコンサルタントのための解雇条件も詳細に規定され、都合による解雇と原因による解雇も特定の財務的影響を持っています。MSAは以前のコンサルティング契約を置き換え、同意された終了条件が満たされるまで継続されます。MSAの全文はSECの提出書類の展示書10.1に含まれています。
役に立った
役に立たない
